Liminatus Pharma (LIMN) Stock Forecast and Price Target (2026)
Last updated July 2026
Short answer
There is no meaningful analyst consensus for Liminatus Pharma (LIMN): too few analysts publish estimates on it for an average target to mean anything. That is normal for smaller and newer companies and says nothing about the business. What is left is the setup, the drivers and the risks below, which you assess yourself rather than starting from someone else's model. Walnut is not an investment adviser.
Why LIMN has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with LIMN. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.
For a clinical-stage biotech with no revenue, traditional metrics like P/E or price-to-sales do not apply, so the numbers that matter are cash on hand, the quarterly cash burn, and the runway between them. Here the runway is very short: a roughly $1 million quarterly loss against under $2 million in cash means the company must keep raising money to operate, which is why management disclosed going concern doubt. Read the market cap as the market's small, heavily discounted estimate of a binary pipeline rather than a multiple of any earnings, and treat each financing and clinical update as the real value driver.
What could move LIMN from here
In short: the drivers cited most often are Lead anti-CD47 program, Pipeline breadth and the InnocsAI merger, Financing is the immediate driver. The risk cited most often against it is liminatus carries the full stack of risks that define a distressed pre-revenue biotech.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the LIMN is it a buy page. This page deliberately stops at the numbers.
Investing in Liminatus Pharma with AI
Connect the broker you already use and ask Walnut's AI how LIMN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the price target for Liminatus Pharma (LIMN)?
+
There is no meaningful consensus price target for LIMN, because too few analysts publish on it. That is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does LIMN have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean you are doing the analysis yourself rather than starting from someone else's model.
What could move LIMN?
+
The drivers and the risks are laid out on this page and in more depth on the LIMN "is it a buy" page. Without analyst estimates to anchor to, the honest framing is scenarios rather than a number.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a August 2026 data pull of published third-party research, are approximate, and change constantly. Verify current figures with your broker before acting on them.